GENFIT Announces Advances in ACLF Pipeline at AASLD The Liver Meeting® 2025

GENFIT, a biopharmaceutical company, announced its participation in the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2025. The company will present new data on its Acute on-Chronic Liver Failure (ACLF) pipeline, including G1090N (a reformulation of nitazoxanide), SRT-015 (an ASK1 inhibitor), and CLM-022 (an NLRP3 inflammasome inhibitor). These presentations will highlight the efficacy of these compounds in preclinical models and their potential to address systemic inflammation and organ function in ACLF. Additionally, GENFIT will present real-world evidence and biomarker insights in cirrhosis. Partner Ipsen will also present new data on Iqirvo® in Primary Biliary Cholangitis (PBC) and Primary Sclerosing Cholangitis (PSC), underscoring its potential in rare cholestatic liver diseases. GENFIT will organize two events focusing on ACLF during the meeting.